Search results for " Pharmaceutic"

showing 10 items of 865 documents

Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo

2021

Multidrug resistance (MDR) mediated by ATP binding cassette subfamily B member 1 (ABCB1) is significantly hindering effective cancer chemotherapy. However, currently, no ABCB1-inhibitory drugs have been approved to treat MDR cancer clinically, mainly due to the inhibitor specificity, toxicity, and drug interactions. Here, we reported that three polyoxypregnanes (POPs) as the most abundant constituents of Marsdenia tenacissima (M. tenacissima) were novel ABCB1-modulatory pro-drugs, which underwent intestinal microbiota-mediated biotransformation in vivo to generate active metabolites. The metabolites at non-toxic concentrations restored chemosensitivity in ABCB1-overexpressing cancer cells v…

ABCC1 ATP binding cassette subfamily C member 1IC50 half maximal inhibitory concentrationMultidrug resistancePharmacologyNADPH reduced nicotinamide adenine dinucleotide phosphateF bioavailabilitychemistry.chemical_compoundPCR polymerase chain reaction0302 clinical medicineMDR multidrug resistanceECL electrochemiluminescencet1/2 elimination half-lifeLC–MS liquid chromatography coupled with mass spectrometryN.D. not detectedGeneral Pharmacology Toxicology and PharmaceuticsBBB blood–brain barriermedia_commonATF3 activating transcription factor 30303 health sciencesChemistryABC ATP-binding cassetteNMPA National Medical Products AdministrationPXR pregnane X receptorSDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresisHBSS Hankʹs balanced salt solutionABCB1Combination chemotherapyProdrugMarsdenia tenacissimaCmax peak concentrationPaclitaxelGAPDH glyceraldehyde-3-phosphate dehydrogenase030220 oncology & carcinogenesisBHI brain heart infusionOriginal ArticleAUC0–∞ area under plasma concentration vs. time curveMRT mean residence timeDrugmedia_common.quotation_subjectRM1-950Vd volume of distributionABCB1 ATP binding cassette subfamily B member 1UIC-2 mouse monoclonal ABCB1 antibodyABCG2 ATP binding cassette subfamily G member 2Combination chemotherapyCYP cytochrome P450 isozymePI propidium iodideTEER transepithelial electrical resistance03 medical and health sciencesPBS phosphate buffer salineFBS fetal bovine serumDox doxorubicinIn vivoPOP polyoxypregnanemedicine030304 developmental biologyEVOM epithelial tissue voltohmmeterTmax time for peak concentrationCancerLBE lowest binding energyPE phycoerythrinmedicine.diseaseMultiple drug resistancePolyoxypregnanePapp apparent permeabilityN.A. not applicableCancer cellH&E hematoxylin and eosinMDR1a multidrug resistance protein 1aTherapeutics. PharmacologyqPCR quantitative PCRM. tenacissima Marsdenia tenacissimaCL clearanceSD standard derivationActa Pharmaceutica Sinica B
researchProduct

Inducible ASABF-Type Antimicrobial Peptide from the Sponge Suberites domuncula: Microbicidal and Hemolytic Activity in Vitro and Toxic Effect on Moll…

2011

Since sponges, as typical filter-feeders, are exposed to a high load of attacking prokaryotic and eukaryotic organisms, they are armed with a wide arsenal of antimicrobial/cytostatic low-molecular-weight, non-proteinaceous bioactive compounds. Here we present the first sponge agent belonging to the group of ASABF-type antimicrobial peptides. The ASABF gene was identified and cloned from the demospongeSuberites domuncula. The mature peptide, with a length of 64 aa residues has a predicted pI of 9.24, and comprises the characteristic CSαβ structural motif. Consequently, the S. domuncula ASABF shares high similarity with the nematode ASABFs ; it is distantly related to the defensins. The recom…

ASABFAntimicrobial peptidesGastropodaMolecular Sequence DataPharmaceutical SciencePeptideMicrobial Sensitivity TestsGram-Positive BacteriaReal-Time Polymerase Chain ReactionArticleMicrobiology03 medical and health sciencesantimicrobial peptidesAnti-Infective AgentsSequence Analysis ProteinDrug DiscoveryAnimalsBittium sp.Structural motiflcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)spongesPhylogeny030304 developmental biologychemistry.chemical_classification0303 health sciencesbiology030306 microbiologyEffectorHemolytic AgentsapoptosisGeologyBittium spsponges; <em>Suberites domuncula</em>; ASABF; antimicrobial peptides; apoptosis; <em>Bittium</em> sp.biology.organism_classificationSuberites domunculasponges ; Suberites domuncula ; ASABF ; antimicrobial peptides ; apoptosis ; Bittium sp.Recombinant ProteinsSuberites domunculaSpongeEnzymelcsh:Biology (General)chemistryMolluscaSuberitesSuberitesAntimicrobial Cationic PeptidesMarine Drugs
researchProduct

Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transpo…

2021

Orally dosed drugs must dissolve in the gastrointestinal (GI) tract before being absorbed through the epithelial cell membrane. In vivo drug dissolution depends on the GI tract's physiological conditions such as pH, residence time, luminal buffers, intestinal motility, and transit and drug properties under fed and fasting conditions (Paixao, P. et al. Mol. Pharm. 2018 and Bermejo, et al. M. Mol. Pharm. 2018). The dissolution of an ionizable drug may benefit from manipulating in vivo variables such as the environmental pH using pH-modifying agents incorporated into the dosage form. A successful example is the use of such agents for dissolution enhancement of BCS class IIb (high-permeability,…

Absorption (pharmacology)Chemistry PharmaceuticalAdministration OralBiological AvailabilityPharmaceutical ScienceModels BiologicalDosage formAcid dissociation constantExcipientsFumaratesDrug DiscoveryHumansComputer SimulationDissolution testingSolubilityTartratesDissolutionChromatographyChemistryHydrogen-Ion ConcentrationStomach emptyingBetaineDrug LiberationSolubilityGastrointestinal AbsorptionDrug DesignMolecular MedicineWeak baseMolecular Pharmaceutics
researchProduct

New prospective in treatment of Parkinson's disease: Studies on permeation of ropinirole through buccal mucosa

2012

The aptitude of ropinirole to permeate the buccal tissue was tested using porcine mucosa mounted on Franz-type diffusion cells as ex vivo model. Drug permeation was also evaluated in presence of various penetration enhancers and in iontophoretic conditions. Ropinirole, widely used in treatment of motor fluctuations of Parkinson's disease, passes the buccal mucosa. Flux and permeability coefficient values suggested that the membrane does not appear a limiting step to the drug absorption. Nevertheless, an initial lag time is observed but the input rate can be modulated by permeation enhancement using limonene or by application of electric fields. Absorption improvement was accompanied by the …

Absorption (pharmacology)IndolesTime FactorsSwinePharmaceutical SciencePharmacologyModels BiologicalPermeabilityAntiparkinson AgentsBuccal delivery Ropinirole Parkinson's disease Absorption enhancement Porcine buccal mucosaDrug Delivery SystemsElectricityCyclohexenesmedicineAnimalsAdjuvants PharmaceuticIontophoresisTerpenesChemistryMouth MucosaAdministration BuccalParkinson DiseasePenetration (firestop)Buccal administrationIontophoresisPermeationRopiniroleMembraneSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoFeasibility StudiesLimoneneEx vivomedicine.drugBiomedical engineeringInternational Journal of Pharmaceutics
researchProduct

Synthesis of polymeric derivatives of isoniazid: characterization and in vitro release from a water-soluble adduct with polysuccinimide.

1989

Coupling of isoniazid with polysuccinimide afforded a water-insoluble polymeric pro-drug; by reaction with ethanolamine it was chemically transformed in a water-soluble adduct. The in vitro release of isoniazid from the drug-polymer adduct was studied by using an artificial stomach wall lipid membrane. The transfer rate constant from simulated gastric juice to simulated plasma was defined and compared with that of an equivalent dose of pure drug.

Absorption of waterChemistryChemistry PharmaceuticalIsoniazidSuccinimidesGeneral ChemistryGeneral MedicineIn vitroAdductchemistry.chemical_compoundWater solubleEthanolamineSolubilityDrug DiscoverymedicineIsoniazidOrganic chemistryLipid bilayerTransfer rate constantmedicine.drugNuclear chemistryChemicalpharmaceutical bulletin
researchProduct

Determination of free formaldehyde in cosmetics containing formaldehyde-releasing preservatives by reversed-phase dispersive liquid-liquid microextra…

2017

Abstract An analytical method for the determination of traces of formaldehyde in cosmetic products containing formaldehyde-releasing preservatives has been developed. The method is based on reversed-phase dispersive liquid–liquid microextraction (RP-DLLME), that allows the extraction of highly polar compounds, followed by liquid chromatography–ultraviolet/visible (LC–UV/vis) determination with post-column derivatization. The variables involved in the RP-DLLME process were studied to provide the best enrichment factors. Under the selected conditions, a mixture of 500 μL of acetonitrile (disperser solvent) and 50 μL of water (extraction solvent) was rapidly injected into 5 mL of toluene sampl…

AcetonitrilesLiquid Phase Microextraction02 engineering and technologyCosmetics01 natural sciencesBiochemistryChemistry Techniques AnalyticalAnalytical Chemistrychemistry.chemical_compoundLimit of DetectionFormaldehydeAcetonitrileDerivatizationDetection limitChromatographyElution010401 analytical chemistryOrganic ChemistryExtraction (chemistry)Preservatives PharmaceuticalReproducibility of ResultsWaterGeneral Medicine021001 nanoscience & nanotechnology0104 chemical sciencesSolventchemistryReagentSolvents0210 nano-technologyEnrichment factorChromatography LiquidTolueneJournal of chromatography. A
researchProduct

OHP-041 Formulary Decision-Making For Biosimilars: Considerations For Hospital Pharmacists

2013

Background It has been 6 years since the first biosimilar was approved for use in the European Union (EU). Given the likelihood that biosimilar monoclonal antibodies will be approved in Europe in the near future, it is timely to review the formulary selection criteria for biologicals and biosimilars. The European Medicines Agency (EMA) has issued guidelines that define the regulation of biosimilars in Europe and recommend approaches to establish biosimilarity. However, several questions regarding the assessment of biosimilars for formulary inclusion remain unanswered, including those related to manufacturing and drug supply. Purpose To aid hospital pharmacists in developing evaluation crite…

Actuarial sciencebusiness.industrySupply chainmedia_common.quotation_subjectBiosimilarHealth caremedia_common.cataloged_instanceMedicineQuality (business)Product (category theory)Supply chain securityGeneral Pharmacology Toxicology and PharmaceuticsFormularyEuropean unionbusinessmedia_commonEuropean Journal of Hospital Pharmacy
researchProduct

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

2021

Objectives Genetic variability in anthracycline metabolism could modify the response and safety of acute myeloid leukemia (AML) induction. Methods Polymorphisms in genes that encodes enzymes of anthracyclines metabolic pathway (CBR3: rs1056892, rs8133052, NQO1: rs1800566, NQO2: rs1143684, NOS3: rs1799983, rs2070744) were evaluated in 225 adult de novo AML patients. Results The variant CBR3 rs8133052 was associated with lower hepatotoxicity (P = 0.028). Wild-type genotype of NQO2 rs1143684 was related to higher complete remission (P = 0.014), and the variant allele with greater gastrointestinal toxicity (P = 0.024). However, the variant genotype of NQO1 rs1800566 was associated with mucositi…

Adult0301 basic medicineAnthracycline030226 pharmacology & pharmacyNephrotoxicity03 medical and health sciences0302 clinical medicineGenotypeGeneticsmedicineMucositisHumansIdarubicinAnthracyclinesGenetic variabilityGeneral Pharmacology Toxicology and PharmaceuticsMolecular BiologyAllelesGenetics (clinical)Polymorphism Geneticbusiness.industryInduction chemotherapyMyeloid leukemiaInduction Chemotherapymedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyCancer researchMolecular Medicinebusinessmedicine.drugPharmacogenetics and Genomics
researchProduct

Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release?

2012

Abstract Background Immunosuppressive therapy after orthotopic liver transplantation (OLT) requires a high degree of patient compliance to guarantee safety and avoid side effects. In 2007, prolonged-release tacrolimus was launched in Europe to improve compliance. In this prospective observational crossover single-center trial, we analyzed effects and side effects of prolonged-release tacrolimus in OLT patients. Methods LT patients at our center were included if they were older than l8 years of age, had had the procedure at least 6 months prior, and were outpatients currently on twice-daily tacrolimus. Patients were observed for 6 months before switching to once-daily tacrolimus. Patient his…

AdultGraft RejectionMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentChemistry Pharmaceuticalchemical and pharmacologic phenomenaLiver transplantationGastroenterologyTacrolimuschemistry.chemical_compoundPharmacotherapyDiabetes mellitusInternal medicineGermanymedicineHumansMedical historyProspective StudiesProspective cohort studyAgedTransplantationCross-Over Studiesbusiness.industryGraft SurvivalMiddle Agedmedicine.diseaseCrossover studyTacrolimusSurgeryLiver Transplantationsurgical procedures operativeTreatment OutcomechemistryDelayed-Action PreparationsSurgeryDrug Therapy CombinationFemaleGlycated hemoglobinbusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age

2006

This study is aimed to verify the modifications of extracellular superoxide dismutase (EC-SOD) activity and its potential involvement on the mechanism responsible for the impairment of plasma nitric oxide (NO) availability occurring with advancing age in healthy humans. For this purpose, plasma samples were drawn from 40 healthy men, aged 20-92 years, in fasting state and used for measurements of stable end-product nitrite/nitrate (NOx), as expression of NO availability, EC-SOD activity, thiobarbituric acid reactive substances (TBARS) as marker of lipid peroxidation, Trolox equivalent antioxidant capacity (TEAC) as a measure of plasma total antioxidant capacity, and in vitro susceptibility …

AdultMaleAgingmedicine.medical_specialtyAntioxidantThiobarbituric acidextracellular superoxide dismutasemedicine.medical_treatmentTrolox equivalent antioxidant capacitymedicine.disease_causeAntioxidantsGeneral Biochemistry Genetics and Molecular BiologyNitric oxideLipid peroxidationchemistry.chemical_compoundNitric oxide Extracellular superoxide dismutase ; Oxidative stress; Advancing ageadvancing agenitric oxideInternal medicinemedicineTBARSAnimalsHumansoxidative stressGeneral Pharmacology Toxicology and PharmaceuticsAgedAged 80 and overSuperoxide DismutaseFastingGeneral MedicineMiddle AgedLipidsEndocrinologychemistryBiochemistryLow-density lipoproteinLipid PeroxidationExtracellular SpaceOxidative stressLife Sciences
researchProduct